Immunosenescence in rheumatoid arthritis: Use of CD28 negative T cells to predict treatment response

4^th International Conference and Exhibition on Biologics & Biosimilars

October 26-28, 2015 Baltimore, USA

Subir Roy

Zydus Cadila, India

Posters-Accepted Abstracts: J Bioanal Biomed

Abstract :

Recent data tend to suggest that immune system in Rheumatoid Arthritis (RA) might be in a state of decline and this weakened state results in demise of the tolerance mechanisms. Expansion of CD28-ve T cells is characteristically seen in RA; infact it precedes development of RA. Rising count of CD28-ve T Cells is a hallmark of immune-senescence. With successful management of RA, CD28-ve T cells count falls. Not many years ago achieving remission in rheumatoid arthritis was difficult due to lack of effective treatment. With the advent of biologics, remission is very much within reach. But biologics are expensive. And not all patients respond adequately to biologics. Hence it will be useful if we have a marker which predicts response to any disease modifying antirheumatic drug (DMARD), whether conventional or biologic. Newer biomarkers are constantly being looked at and CD28-ve T cells is one of them.

Biography :

Email: subir_lives@yahoo.com